In this practical randomized clinical trial, the clinical integration of SLCO1B1 pharmacogenetic testing for simvastatin myopathy risk did not result in poorer measures of ASCVD prevention in routine primary care settings. This evidence concerns the gene SLCO1B1 and myopathy.